Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (71-80 of 235) with videos related to

Pageof 24
Sort By:
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
The Lancet. Oncology|January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointMatthew D Hellmann, Jamie E Chaft, William N William, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Leukemia & Lymphoma|June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory diseaseJacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant TumorsNarek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.
Pageof 24

Showing results (71-80 of 235) with videos related to

Sort By:
Pageof 24
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
The Lancet. Oncology|January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointMatthew D Hellmann, Jamie E Chaft, William N William, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Leukemia & Lymphoma|June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory diseaseJacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant TumorsNarek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.
Pageof 24